QUINCY, Mass.--(BUSINESS WIRE)--WOUNDCHEK™ Laboratories announced today that it is partnering with the SerenaGroup™, a US wound care centre network of 20 clinics, to complete two clinical trials in 2014 aimed at gaining FDA clearance of both WOUNDCHEK™ Protease Status (which is already available in Europe, the Middle East, and South Africa) and WOUNDCHEK™ Bacterial Status, a new test in development to assess bacterial pathogenicity in chronic wounds.
Leading US wound care practitioners agree that point of care diagnostic tests developed specifically to aid chronic wound care could dramatically change the provision of care, especially in outpatient settings1,2. WOUNDCHEK™ Protease Status is the world’s first point of care test to detect elevated protease activity (EPA) in chronic wounds. A chronic wound with EPA has a 90% probability it won’t heal without appropriate protease modulating intervention3. Recent studies have further shown that chronic wounds with EPA carry a significantly higher probability of graft failure than chronic wounds with low protease activity4,5.
Help employers find you! Check out all the jobs and post your resume.
